What are the differences between auto‑allergic chronic urticaria and autoimmune (type IIb) chronic urticaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Difference Between Auto-Allergic and Auto-Immune Urticaria

Auto-allergic (Type I) and autoimmune (Type IIb) chronic spontaneous urticaria represent two distinct pathophysiological mechanisms of mast cell activation, differentiated primarily by antibody type: Type I involves IgE autoantibodies against self-antigens (autoantigens), while Type IIb involves IgG autoantibodies that directly activate mast cells via FcεRI and/or IgE. 1

Key Pathophysiological Distinctions

Type I Auto-Allergic CSU

  • Mechanism: IgE autoantibodies directed against self-antigens (e.g., thyroid peroxidase, IL-24) cause FcεRI crosslinking on mast cells 2, 3
  • Immunologic profile: Elevated total IgE levels (≥40 IU/mL) 2, 4
  • Associated features:
    • Presence of atopic diseases (allergic rhinitis, asthma)
    • Positive skin tests to inhalant allergens
    • More common presentation (38% of CSU patients in one cohort) 4

Type IIb Autoimmune CSU

  • Mechanism: IgG (or IgM) autoantibodies activate mast cells directly through FcεRI and/or anti-IgE antibodies 1, 3
  • Immunologic profile: Low or very low total IgE levels (<40 IU/mL) 2, 3
  • Associated features:
    • Concomitant autoimmune diseases (especially autoimmune thyroid disease)
    • Elevated IgG-anti-thyroid peroxidase (anti-TPO) levels
    • Positive autologous serum skin test
    • Positive antinuclear antibodies (≥1:160 titer)
    • Basopenia and eosinopenia 4, 3
    • Present in less than 10% of CSU patients when strict criteria applied (triple positivity: autologous serum skin test, immunoassays for IgG autoantibodies, and basophil activation tests) 3

Clinical Implications and Treatment Response

The distinction matters clinically because Type IIb autoimmune CSU demonstrates:

  • Higher disease severity 3
  • Poor response to H1-antihistamines 3, 5
  • Poor response to omalizumab 3, 5
  • Good response to cyclosporine 3, 5
  • Potential response to Bruton's tyrosine kinase inhibitors 5

Type I auto-allergic CSU typically shows:

  • Better response to standard antihistamine therapy
  • Better response to omalizumab (anti-IgE therapy) 2

Diagnostic Approach

The most practical surrogate marker for Type IIb autoimmune CSU is a high ratio of IgG-anti-TPO to total IgE 2. Basic testing should include:

  • Total IgE level
  • IgG-anti-TPO level
  • Differential blood count (looking for basopenia/eosinopenia)
  • C-reactive protein/ESR 2

Important Caveats

A substantial overlap exists between these endotypes: 51% of patients in one study showed features of both Type I and Type IIb (mixed endotype) 4. Additionally, some patients (2-3%) show neither endotype pattern 4, 6. This overlap complicates clean categorization and suggests that many patients have multiple pathogenic mechanisms operating simultaneously 7, 8.

The autologous serum skin test, while suggested for diagnosis of auto-reactive disease, has limited clinical relevance since omalizumab efficacy is independent of test results 2.

Practical Clinical Algorithm

When evaluating CSU patients:

  1. Measure total IgE and IgG-anti-TPO levels at baseline 2
  2. Calculate the anti-TPO/total IgE ratio - high ratio suggests Type IIb 2
  3. Check for basopenia and eosinopenia - associated with Type IIb 4, 3
  4. Assess for autoimmune comorbidities - particularly thyroid disease 3
  5. Consider treatment sequencing based on endotype:
    • If Type IIb features predominate (low IgE, high anti-TPO, poor antihistamine response): consider earlier use of cyclosporine rather than prolonged omalizumab trials 3, 5
    • If Type I features predominate (high IgE, atopic background): standard stepwise approach with antihistamines then omalizumab is appropriate 2

The field is moving toward biomarker-driven personalized care, though standardized, widely accessible testing remains an unmet need 8, 9.

References

Guideline

chronic spontaneous urticaria guidelines: what is new?

Journal of Allergy and Clinical Immunology, 2022

Research

Autoimmune chronic spontaneous urticaria.

The Journal of allergy and clinical immunology, 2022

Research

Chronic spontaneous urticaria: new evidences on the role of autoimmunity.

Current opinion in allergy and clinical immunology, 2023

Research

Endotypes of chronic spontaneous urticaria at a tertiary care hospital.

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 2026

Research

Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025

Research

Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2025

Research

Management of chronic urticaria: Current status and future prospect.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.